Life Sciences Tools and Services
Company Overview of Hadasit Medical Research Services & Development Ltd.
Hadasit Medical Research Services & Development Ltd. promotes and commercializes its parent company’s intellectual property, and wealth of pre-clinical and clinical research and development capabilities through product licensing, establishing start-up companies, and collaboration with academy and industry. It promotes pre-clinical research services that are offered to biotechnology, pharmaceutical, and medical device industries. The company also handles the contractual aspects of various clinical trials. It promotes pre-clinical research services in the areas of cell biology, clinical diagnostics, consultations and counseling, disease models and experimental surgery, drug discovery, genetics...
Founded in 1986
Key Executives for Hadasit Medical Research Services & Development Ltd.
Vice President of Finance & Contracts
Vice President of Business Development, Therapeutics and Diagnostics
Compensation as of Fiscal Year 2015.
Hadasit Medical Research Services & Development Ltd. Key Developments
BioLineRx Signs License Agreement with Yissum Research Development Company, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd
Oct 23 13
BioLineRx announced that it has signed a worldwide, exclusive license agreement with Yissum Research Development Company, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd. for BioLineRx to develop and commercialize BL-9020, for the treatment of Type 1 diabetes. Promising results of preclinical studies in a mouse model of Type 1 diabetes demonstrated that BL-9020 is able to inhibit the onset of diabetes. Previously, the project was developed under BioLineRx's Early Development Program as EDP-10. BL-9020 is a novel antibody treatment for prevention of the development of Type 1 diabetes. It was developed to treat Type 1 diabetes in early stage patients, during what is known as the 'honeymoon period'. At this early stage of the disease, the insulin-producing pancreatic cells are not completely destroyed and continue to secrete insulin. Pre-clinical studies suggest that BL-9020 can preserve surviving cells, thus preventing full maturation of the disease.
Hadasit and AstraZeneca PLC to Collaborate on Discovering and Developing Treatments for Cancer, Diabetes, and Respiratory Diseases
Sep 23 13
Hadasit and AstraZeneca plc will collaborate on discovering and developing treatments for cancer, diabetes, and respiratory diseases. The terms of the deal were not disclosed, but they probably include a small initial payment by AstraZeneca to Hadasit. Payments may increase if and when jointly discovered products move forward in AstraZeneca's pipeline. AstraZeneca will also be responsible for commercialization of products, if and when they reach market. Hadasit and Hadassah scientists will work in collaboration with teams from AstraZeneca's Innovative Medicines & Early Development organization for an initial period of three years.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries